The impact of pneumococcal conjugate vaccine-13 on the incidence of pediatric community-acquired bacteremia.
Bacteremia
/ epidemiology
Bacteria
/ isolation & purification
Child
Child, Preschool
Cohort Studies
Community-Acquired Infections
/ epidemiology
Female
Hospitals, University
Humans
Incidence
Infant
Israel
/ epidemiology
Male
Penicillin Resistance
Pneumococcal Vaccines
Retrospective Studies
Tertiary Care Centers
Bacteremia
Community
Pediatric
Pneumococcal vaccine
Streptococcus pyogenes
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
10
10
2020
accepted:
14
01
2021
pubmed:
5
2
2021
medline:
9
10
2021
entrez:
4
2
2021
Statut:
ppublish
Résumé
The purpose of this study was to estimate the impact of pneumococcal conjugate vaccine-13 (PCV-13) introduction into the national immunization program in Israel on pneumococcal and non-pneumococcal pediatric community-acquired bacteremia (CAB). This is a retrospective cohort study, including children ≤ 18 years old with CAB, who were hospitalized in Rambam Health Care Campus, a tertiary medical center serving northern Israel, between the years 2004 and 2016. The proportional admission rate of pneumococcal bacteremia among all CAB events and the incidence of CAB and pneumococcal bacteremia per 1000 hospital admissions were compared between the pre- and post-pneumococcal vaccine eras. A total of 275 CAB events were identified. Common isolates were Streptococcus pneumoniae (SPn) (26.9%), Staphylococcus aureus (12.4%), Brucella spp. (11.6%), E. coli (10.9%), and Streptococcus pyogenes (5.8%). The pneumococcal bacteremia rate per 1000 hospital admissions decreased significantly from 1.59 to 0.6 (p < 0.001). The proportional pneumococcal bacteremia rate decreased from 55 (34.4%) to 19 (16.5%) (p 0.001). Penicillin resistance among pneumococcal isolates decreased dramatically from 50.9 to 5.3% (p < 0.001). The rate of bacteremia caused by other pathogens has not been changed significantly at the post-vaccination era (p 0.053). However, an increase in the incidence of S. pyogenes bacteremia from 1.9 to 11.3% (p < 0.001) was noticed. In addition, an outbreak of Brucella bacteremia occurred during the years 2015-2016. This study demonstrates the double positive effect of PVC-13 introduction: a sharp decrease in the proportional rate of pneumococcal bacteremia and in the resistance of SPn to penicillin. Also, there was a moderate decline in the incidence of CAB in exception to bacteremia caused by S. pyogenes. This trend was reversed due to a Brucella outbreak.
Identifiants
pubmed: 33537906
doi: 10.1007/s10096-021-04167-9
pii: 10.1007/s10096-021-04167-9
doi:
Substances chimiques
13-valent pneumococcal vaccine
0
Pneumococcal Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1433-1439Références
Centers for Disease Control and Prevention (CDC) (2010) Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007. MMWR Morb Mortal Wkly Rep 12(59):253–257. http://www.ncbi.nlm.nih.gov/pubmed/20224541
Song JY, Nahm MH, Moseley MA (2013) Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci 28:4–15. https://doi.org/10.3346/jkms.2013.28.1.4
doi: 10.3346/jkms.2013.28.1.4
pubmed: 23341706
pmcid: 3546102
Hausdorff WP, Feikin DR, Klugman KP (2005) Epidemiological differences among pneumococcal serotypes. Lancet Infect Dis [cited 2021 2];5:83–93. https://pubmed.ncbi.nlm.nih.gov/15680778/ . https://doi.org/10.1016/s1473-3099(05)01280-6
Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S et al (2014) Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine [cited 2021 2];32:3452–3459. https://pubmed.ncbi.nlm.nih.gov/24690148/ . https://doi.org/10.1016/j.vaccine.2014.03.065
Ribitzky-Eisner H, Minuhin Y, Greenberg D, Greenberg N, Chodick G, Craiu M et al (2016) Epidemiologic and microbiologic characteristics of occult bacteremia among febrile children in southern Israel, before and after initiation of the routine antipneumococcal immunization (2005–2012). Pediatr Neonatol [cited 2021 2];57:378–384. https://pubmed.ncbi.nlm.nih.gov/26738763/ . https://doi.org/10.1016/j.pedneo.2015.10.004
Leibovitz E, David N, Ribitzky-Eisner H, Madegam MA, Abuabed S, Chodick G et al (2016) The epidemiologic, microbiologic and clinical picture of bacteremia among febrile infants and young children managed as outpatients at the emergency room, before and after initiation of the routine anti-pneumococcal immunization. Int J Environ Res Public Health [cited 2021 2];13. https://pubmed.ncbi.nlm.nih.gov/27447651/ . https://doi.org/10.3390/ijerph13070723
Berger Y, Adler A, Ariel T, Rokney A, Averbuch D, Grisaru-Soen G (2019) Paediatric community-acquired bacteraemia, pneumococcal invasive disease and antibiotic resistance fell after the pneumococcal conjugate vaccine was introduced. Acta Paediatr Int J Paediatr [cited 2021 2];108:1321–1328. https://pubmed.ncbi.nlm.nih.gov/30506762/ . https://doi.org/10.1111/apa.14670
Buetti N, Atkinson A, Kottanattu L, Bielicki J, Marschall J, Kronenberg A et al (2017) Patterns and trends of pediatric bloodstream infections: a 7-year surveillance study. Eur J Clin Microbiol Infect Dis [cited 2021 2];36:537–544. https://pubmed.ncbi.nlm.nih.gov/27885442/ . https://doi.org/10.1007/s10096-016-2830-6
Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ et al (2013) Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 32:203–207. https://doi.org/10.1097/INF.0b013e318275614b
doi: 10.1097/INF.0b013e318275614b
pubmed: 23558320
Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MPE, Miller E (2015) Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis 1(15):535–543. https://doi.org/10.1016/S1473-3099(15)70044-7
doi: 10.1016/S1473-3099(15)70044-7
Herz AM, Greenhow TL, Alcantara J, Hansen J, Baxter RP, Black SB et al (2006) Changing epidemiology of outpatient bacteremia in 3- to 36-month-old children after the introduction of the heptavalent-conjugated pneumococcal vaccine. Pediatr Infect Dis J [cited 2021 2];25:293–300. https://pubmed.ncbi.nlm.nih.gov/16567979/ . https://doi.org/10.1097/01.inf.0000207485.39112.bf
CDC, Ncezid, DHQP (2021) Bloodstream infection event (central line-associated bloodstream infection and non-central line associated bloodstream infection)
M100 Performance Standards for Antimicrobial Susceptibility Testing A CLSI supplement for global application. [cited 2021 6]. www.clsi.org
Ben-Shimol S, Greenberg D, Hazan G, Givon-Lavi N, Gottesman G, Grisaru-Soen G et al (2015) Differential impact of pneumococcal conjugate vaccines on bacteremic pneumonia versus other invasive pneumococcal disease. Pediatr Infect Dis J [cited 2021 2];34:409–416. https://pubmed.ncbi.nlm.nih.gov/25764098/ . https://doi.org/10.1097/INF.0000000000000604
Irwin AD, Drew RJ, Marshall P, Nguyen K, Hoyle E, Macfarlane KA et al (2015) Etiology of childhood bacteremia and timely antibiotics administration in the emergency department. Pediatrics [cited 2021 2];135:635–642. https://pubmed.ncbi.nlm.nih.gov/25755240/ . https://doi.org/10.1542/peds.2014-2061
Ciapponi A, Elorriaga N, Rojas JI, Romano M, Martí SG, Bardach A et al (2014) Epidemiology of pediatric pneumococcal meningitis and bacteremia in Latin America and the Caribbean: a systematic review and meta-analysis. Pediatr Infect Dis J [cited 2021 2];33:971–978. https://pubmed.ncbi.nlm.nih.gov/24830699/ . https://doi.org/10.1097/INF.0000000000000363
A Retrospective Study of the Impact of Pneumococcal Conjugate Vaccine-13 Immunization in a northern Israel hospital - PubMed. [cited 2021 2]. https://pubmed.ncbi.nlm.nih.gov/32043321/
Emergence of Streptococcus pneumoniae serotype 12F after sequential introduction of7- and 13-valent vaccines - Google Search. [cited 2021 6]. https://www.google.com/search?sxsrf=ALeKk01gTryWtLaHIsobj5aY9i4A3zOg9Q%3A1609888838989&ei=RvT0X4D7O4z8sAfxhqW4CQ&q=Emergence+of+Streptococcus+pneumoniae+serotype+12F+after+sequential+introduction+of7-+and+13-valent+vaccines+&oq=Emergence+of+Streptococcus+pneumoniae+serotype+12F+after+sequential+introduction+of7-+and+13-valent+vaccines+&gs_lcp=CgZwc3ktYWIQAzIHCAAQRxCwAzIHCAAQRxCwAzIHCAAQRxCwAzIHCAAQRxCwAzIHCAAQRxCwAzIHCAAQRxCwAzIHCAAQRxCwAzIHCAAQRxCwA1CsmVlYrJlZYOyfWWgDcAJ4AIABAIgBAJIBAJgBAKABAqABAaoBB2d3cy13aXrIAQjAAQE&sclient=psy-ab&ved=0ahUKEwiAtoCj94XuAhUMPuwKHXFDCZcQ4dUDCA0&uact=5
Liyanapathirana V, Nelson EAS, Ang I, Subramanian R, Ma H, Ip M (2015) Emergence of serogroup 15 Streptococcus pneumoniae of diverse genetic backgrounds following the introduction of pneumococcal conjugate vaccines in Hong Kong. Diagn Microbiol Infect Dis [cited 2021 2];81:66–70. https://pubmed.ncbi.nlm.nih.gov/25445117/ . https://doi.org/10.1016/j.diagmicrobio.2014.09.028
Makarewicz O, Lucas M, Brandt C, Herrmann L, Albersmeier A, Rückert C et al (2017) Whole genome sequencing of 39 invasive Streptococcus pneumoniae sequence type 199 isolates revealed switches from serotype 19A to 15B. PLoS One [cited 2021 2];12. https://pubmed.ncbi.nlm.nih.gov/28046133/ . https://doi.org/10.1371/journal.pone.0169370
Kim L, McGee L, Tomczyk S, Beall B (2016) Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine eras: a United States perspective. Clin Microbiol Rev [cited 2021 2];29:525–552. https://pubmed.ncbi.nlm.nih.gov/27076637/. https://doi.org/10.1128/CMR.00058-15
Liese JG, Schoen C, van der Linden M, Lehmann L, Goettler D, Keller S et al (2019) Changes in the incidence and bacterial aetiology of paediatric parapneumonic pleural effusions/empyema in Germany, 2010–2017: a nationwide surveillance study. Clin Microbiol Infect 1(25):857–864. https://doi.org/10.1016/j.cmi.2018.10.020
doi: 10.1016/j.cmi.2018.10.020
Stankey CT, Spaulding AB, Doucette A, Hamre KES, Wheeler W, Pomputius WF et al (2018) Blood culture and pleural fluid culture yields in pediatric empyema patients: a retrospective review, 1996-2016. Pediatr Infect Dis J [cited 2021 2];37:952–954. https://pubmed.ncbi.nlm.nih.gov/29438130/ . https://doi.org/10.1097/INF.0000000000001940